<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01112384</url>
  </required_header>
  <id_info>
    <org_study_id>I200</org_study_id>
    <nct_id>NCT01112384</nct_id>
  </id_info>
  <brief_title>A Study of SB939 in Patients With Translocation-Associated Recurrent/Metastatic Sarcomas</brief_title>
  <acronym>IND200</acronym>
  <official_title>A Phase II Study of SB939 in Patients With Translocation-Associated Recurrent/Metastatic Sarcomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NCIC Clinical Trials Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>S*BIO</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Canadian Cancer Trials Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to find out what effects a new drug SB939 has on you and your&#xD;
      sarcoma.&#xD;
&#xD;
      This research is being done because there is a need for better treatment options for advanced&#xD;
      or recurring sarcoma.&#xD;
&#xD;
      SB939 has been shown to shrink tumours in animals and some people and seems promising but it&#xD;
      is not clear if it has any positive effects in sarcoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objectives:&#xD;
&#xD;
        1. - To determine the efficacy of SB939 in translocation associated sarcoma patients.&#xD;
&#xD;
        2. - To determine response duration, stable disease rate and progression free survival.&#xD;
&#xD;
        3. - To evaluate toxicity of SB939.&#xD;
&#xD;
        4. - To investigate potential molecular factors predictive of response.&#xD;
&#xD;
      60mg SB939 will be given every other day 3 times a week for 3 weeks followed by a week off.&#xD;
      Patients may receive a maximum of 12 cycles if they have a response to treatment in the&#xD;
      absence of disease progression or unacceptable toxicity. Patients with stable disease may&#xD;
      continue therapy for a maximum of 6 cycles.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 18, 2010</start_date>
  <completion_date type="Actual">January 16, 2014</completion_date>
  <primary_completion_date type="Actual">January 21, 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the efficacy (as measured by objective response) of SB939 when given orally every other day 3 times a week, in patients with translocation-associated sarcomas.</measure>
    <time_frame>24 months</time_frame>
    <description>The primary endpoint of this study is objective tumour response using RECIST 1.1 [Eisenhauer 2009]. Response is defined as 30% decrease in the sum of the diameters of the target lesions (partial response) maintained for at least 4 weeks, or complete disappearance of disease and cancer related symptoms (complete response), also maintained for at least 4 weeks. The median and range of the duration of response will be assessed. A 95% confidence interval for the true objective response rate will be given.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response duration, stable disease rate and progression free survival in these patients.</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerability and toxicity of SB939, according to NCI CTCAE 4.0, in this population</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Potential molecular factors predictive of response in formalin fixed paraffin embedded specimens of patient sarcoma tissue</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Metastatic Sarcoma</condition>
  <arm_group>
    <arm_group_label>SB939</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SB939</intervention_name>
    <description>Given orally 3 times per week</description>
    <arm_group_label>SB939</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with histologically diagnosed sarcomas that are associated with chromosomal&#xD;
             translocation producing a fusion transcription factor oncogene.&#xD;
&#xD;
          -  Patients must have measurable disease.&#xD;
&#xD;
          -  A tissue block from primary or metastatic tumor must be available for confirmation of&#xD;
             diagnosis, translocation subtype and correlative studies.&#xD;
&#xD;
          -  Up to 1 prior chemotherapy regimen in the metastatic setting is permitted providing 28&#xD;
             days have elapsed.&#xD;
&#xD;
          -  Prior radiation permitted provided a minimum of 28 days have elapsed.&#xD;
&#xD;
          -  Surgery permitted provided at least 3 weeks have elapsed.&#xD;
&#xD;
          -  Prior hormone therapy permitted.&#xD;
&#xD;
          -  Patients must have life expectancy ≥ 12 weeks.&#xD;
&#xD;
          -  Metastatic or locally recurrent disease incurable with standard treatment.&#xD;
&#xD;
          -  Acceptable end-organ function. ECOG 0, 1 or 2.&#xD;
&#xD;
          -  granulocytes ≥1.5x10/9/L&#xD;
&#xD;
          -  platelets ≥100x10/9/L&#xD;
&#xD;
          -  bilirubin ≤UNL&#xD;
&#xD;
          -  potassium ≤UNL&#xD;
&#xD;
          -  calcium, magnesium within normal limits&#xD;
&#xD;
          -  AST, ALT ≤2.5 x UNL&#xD;
&#xD;
          -  serum creatinine ≤UNL or creatinine clearance ≥50mL/min&#xD;
&#xD;
          -  QTc ≤450m sec&#xD;
&#xD;
          -  LVEF ≥50%&#xD;
&#xD;
          -  Troponin I or T ≤ UNL&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Cardiac exclusions; Patients with any preexisting uncontrolled cardiac condition.&#xD;
&#xD;
          -  History of myocardial infarction at any time in the past.&#xD;
&#xD;
          -  Patients with a history of other malignancies, except: adequately treated non-melanoma&#xD;
             skin cancer, curatively treated in-situ cancer of the cervix, or other solid tumors&#xD;
             curatively treated with no evidence of disease for &gt; 5 years.&#xD;
&#xD;
          -  Patients with documented CNS metastases, unless adequately treated with radiation at&#xD;
             least 30 days prior to enrollment. Patients cannot have concurrent anti-convulsants or&#xD;
             dexamethasone for control of symptoms. Patients with leptomeningeal disease, even with&#xD;
             treatment, cannot be enrolled due to generally poor prognosis.&#xD;
&#xD;
          -  Inability to take oral medication. Patients must be able to swallow SB939 capsules and&#xD;
             have no gastrointestinal abnormalities (e.g. bowel obstruction or previous gastric&#xD;
             resection) which would lead to inadequate absorption of SB939.&#xD;
&#xD;
          -  Previous treatment with an HDAC inhibitor.&#xD;
&#xD;
          -  Treatment with another investigational therapy or other anticancer therapy within 28&#xD;
             days prior to study entry.&#xD;
&#xD;
          -  Known HIV, hepatitis B or hepatitis C infections.&#xD;
&#xD;
          -  Dysrhythmic drugs - use of agents with a known risk of Torsades De Pointe is not&#xD;
             permitted during the study. A comprehensive list can be found at http://torsades.org.&#xD;
&#xD;
          -  Presence of any chronic medical condition or comorbidity such as pulmonary disease,&#xD;
             active CNS disease, active infection, psychiatric condition, or laboratory abnormality&#xD;
             that may increase the risks associated with study participation/study drug&#xD;
             administration or may interfere with the interpretation of study results.&#xD;
&#xD;
          -  Women or men who are not sterile unless they use an adequate method of birth control.&#xD;
             Female patients that are post-menopausal for at least 12 months or are surgically&#xD;
             sterile are considered sterile.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Quincy Chu</last_name>
    <role>Study Chair</role>
    <affiliation>Cross Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Tom Baker Cancer Centre</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4N2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cross Cancer Institute</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BCCA - Vancouver Cancer Centre</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 4E6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Juravinski Cancer Centre at Hamilton Health Sciences</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8V 5C2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>London Regional Cancer Program</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 4L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ottawa Health Research Institute - General Division</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ. Health Network-Princess Margaret Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McGill University - Dept. Oncology</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2W 1S6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <link>
    <url>http://annonc.oxfordjournals.org/content/early/2015/01/28/annonc.mdv033.abstract</url>
    <description>Link to abstract</description>
  </link>
  <results_reference>
    <citation>Chu QS, Nielsen TO, Alcindor T, Gupta A, Endo M, Goytain A, Xu H, Verma S, Tozer R, Knowling M, Bramwell VB, Powers J, Seymour LK, Eisenhauer EA. A phase II study of SB939, a novel pan-histone deacetylase inhibitor, in patients with translocation-associated recurrent/metastatic sarcomas-NCIC-CTG IND 200†. Ann Oncol. 2015 May;26(5):973-981. doi: 10.1093/annonc/mdv033. Epub 2015 Jan 28.</citation>
    <PMID>25632070</PMID>
  </results_reference>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 14, 2010</study_first_submitted>
  <study_first_submitted_qc>April 27, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 28, 2010</study_first_posted>
  <last_update_submitted>April 6, 2020</last_update_submitted>
  <last_update_submitted_qc>April 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

